No Near-Term Separations For Pfizer, But Business Model Will “Evolve”
This article was originally published in The Pink Sheet Daily
Beyond the sale of its nutritionals business and spin-out of animal health into Zoetis, no additional separations are planned for Pfizer in the near-term. But CEO Ian Read discussed how he sees the company’s Established Products and Emerging Markets businesses evolving over the long-term, including the potential for an eventual breakout, during a year-end financial call Jan. 29.
You may also be interested in...
Although the company beat estimates and executed on an ambitious late-stage pipeline, analysts on Pfizer’s earnings call were focused on palbociclib, Prevnar, and the pharma’s plans for its established products business.
Pfizer top management hasn’t yet decided whether it will divide in two or stop at a “virtual split.” Plus updates on Lundbeck/Otsuka, Shire/SARcode, AstraZeneca/Actavis, and more.
FDA approved use of the pneumococcal vaccine in children and adolescents aged six to 17 years; uptake in adults 50 and older has been impacted by the delay in getting an ACIP vote on treatment, which is expected later this year.